Inhalation of tobramycin in cystic fibrosis. Part 2: Optimization of the tobramycin solution for a jet and an ultrasonic nebulizer

P.P.H. Le Brun, Anne Boer, de, D. Gjaltema, P. Hagedoorn, H.G.M. Heijerman, H.W. Frijlink

Research output: Contribution to journalArticleAcademicpeer-review

19 Citations (Scopus)

Abstract

The inhalation of tobramycin is part of current cystic fibrosis (CF) therapy. Local therapy with inhaled antibiotics has demonstrated improvements in pulmonary function. Current inhalation therapy is limited by the available drug formulations in combination with the nebulization time. The aim of this study is to develop a highly concentrated tobramycin solution for inhalation. Several tobramycin solutions, ranging from 5 to 30% (m/v), were compared after aerosolation with a jet and with an ultrasonic nebulizer. Laser diffraction and cascade impactor analysis were used for characterization of the aerosolized solutions. The output rate was determined in volume and mass output per minute. From the output rate measurements, it was concluded that a 20% tobramycin solution is the optimal and maximal concentration to be aerosolized. The jet nebulizer was most suitable. Using the jet nebulizer and the 20% solution, it is possible to administer a dosage of 1000 mg tobramycin by inhalation within 30 min. Copyright (C) 1999 Elsevier Science B.V.
Original languageEnglish
Pages (from-to)215-225
Number of pages11
JournalInternational Journal of Pharmaceutics
Volume189
Issue number2
DOIs
Publication statusPublished - 5-Nov-1999

Keywords

  • Cascade impactor
  • Cystic fibrosis
  • Inhalation
  • Laser diffraction
  • Nebulizer
  • Tobramycin
  • tobramycin
  • water
  • aerosol
  • equipment
  • article
  • controlled study
  • cystic fibrosis
  • drug formulation
  • drug solution
  • inhalation
  • intermethod comparison
  • laser diffraction
  • nebulization
  • nebulizer
  • particle size
  • priority journal
  • ultrasound

Cite this